Stockreport

AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices

GlaxoSmithKline PLC  (GSK) 
US:NYSE Investor Relations: gsk.com/en-gb/investors
PDF Over 13 million adults aged 50-59 at increased risk in the US can potentially benefit from RSV immunization1RSV causes an estimated 42,000 hospitalizations* each year in [Read more]